Teva Pharmaceutical Industries Ltd. (TEVA)
Loading...
Symbols:
TEVA Forum Topics
- All Comments on TEVA
- General Discussion on TEVA
- Interview with Jamia Jasper, American Israeli Shared Values Capital Appreciation Fund [view article]
- Pharmaceuticals: Pfizer Is a Buy [view article]
- Indevus: Making Big Gains with Approval for Its New Drug [view article]
- Biotech Names With Big Potential [view article]
- Loss of Integrity - Cramer's Mad Money Recap (9/3/08) [view article]
- Wall Street Breakfast: Must-Know News [view article]
- In Tech We Trust - Fast Money Recap (6/20/08) [view article]
- Big Pharma’s Healthy Appetite for Acquisitions [view article]
- Watch for More Coming Biotech Acquisitions [view article]
- Wall Street Breakfast: Must-Know News [view article]
- Big Biotech Booms But IBB Falls Flat [view article]
- Teva Buys Barr Pharmaceuticals [view article]
loading ...Recent TEVA Articles
- Indevus: Making Big Gains with Approval for Its New Drug
- Pharmaceuticals: Pfizer Is a Buy
- Biotech Names With Big Potential
- Being Short New York - Fast Money Recap (9/22/08)
- Interview with Jamia Jasper, American Israeli Shared Values Capital Appreciation Fund
- Wall Street Breakfast: Must-Know News
- Merger Watch: Barr Pharmaceuticals - Teva Pharmaceutical
- Big Pharma’s Healthy Appetite for Acquisitions
- FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen
- Watch for More Coming Biotech Acquisitions
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Interview with Jamia Jasper, American Israeli Shared Values Capital Appreciation Fund [view article]
Great interview. Keep them coming! ReplyPharmaceuticals: Pfizer Is a Buy [view article]
A slug of PFE is owned by the Fairholme Fund. Fund is managed by very sharp, Bruce Berkowitz. FAIRX is a concentrated fund, (up 13.4% annually over last 5 yrs.), and PFE represents over 10% of its current stock holdings. Yeah I own FAIRX and PFE. And I bought more PFE at the end of Monday, crash day, 9/29/08. ReplyIndevus: Making Big Gains with Approval for Its New Drug [view article]
Thanks for the info Mr. Snyder. Do you think the price will rise back to the $7 to $8 range now or will it settle less on this good news? I own some Jan options in this and was pleasantly surprised by this dose of double good news. It is rare in this market to get excited about anything, but with an over 100% gain in a day, its hard not too. ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Agree on ABT-- solid company. I may add some.I'm long on CVTX, GILD,RDEA, TEVA, JNJ these days. Reply
Pharmaceuticals: Pfizer Is a Buy [view article]
Abbott has a more diversified mix of businesses with diagnostics/nutrionals as summarized below from their last earnings report:-global sales growth of 14.8% to $7.3 billion (B)
-pharmaceutical sales ($4.1B) growth of 16.7% led by Humira (a biological agent for autoimmune diseases such as rheumatoid arthritis), which experienced a 48% growth in sales for 1H08 at $1.1B with a forecast for sales of $4.3 billion for 2008
-medical product sales ($1.4B) growth of 14.7% driven by diagnostics sales ($0.9B) growth over 17%
-nutritional sales ($1.2B) growth of 21.3% thanks to strong results in emerging markets
Abbott Labs reported total sales for the first half of 2008 of $14.1B with $6.5B in the USA and $7.6B internationally. The Company posted a diversified mix of healthcare business units with 56.5% of sales from prescription drugs, 16.5% from nutrional products, 12.5% from diagnostics, and about 6.5% from vascular products such as stents. The Company increased its earnings-per-share guidance from a range of $3.20 - $3.25 to $3.24 - $3.28, excluding specified items, reflecting growth of about 15% along with expected sales growth in the mid-teens for the full year. Reply
Pharmaceuticals: Pfizer Is a Buy [view article]
All the majors down except ABT is up WHY are they up? What does the market see. Do they have lots of things in the pipelines? ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Why not just buy BMY? The yield is 6% and much better growth prospects. ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Celebrex goes off-patent 2012. PFE stock isn't bottomed yet. On the plus side, post 2012, I think things will start to look up for them. ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Pipelines are overrated. No one can predict how a drug will do 5-10 years from now. A promising drug could end up having untolerable adverse reactions and be pulled from the market (i.e. Vioxx, Bextra etc.). A bust drug could end up being an unexpected blockbluster for a completely different condition (i.e. Viagra). In the long run, it all evens out. Pfizer is a good long-term value now with a safe 7% dividend yield and solid balance sheet. In this turbulent market, you could definitely do worse. ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Sanofi looks good too, good enough fior Buffett to buy into it. nice yield there as well. ReplyPharmaceuticals: Pfizer Is a Buy [view article]
Great value, loaded with cash, cash is king now, who needs a pipeline, the way things are going they can buy anything they want cheaply with all their cash and/or raise more w debt ala Microsoft with their high ratings.Recently increased marketing for lipitor and chantix will keep things moving up.
Lyrica is the real sleeper in this portfolio, anything that helps with pain is going to be hot. Neuropathy is a painful condition, I have it, and this drug works wonders. Neuropathy via Diabetes is growing problem.
Plus don't forget Celebrex. The pipeline is full of goodies.
So buy buy buy and forget the 0.5% you can get on tbills, collect the div. I bet they raise div to 1.40 too. With earnings of about 2.10-2.20 they coudl afford it. thats makes the wait and see yield about 8%
Long/Buy! Reply
Pharmaceuticals: Pfizer Is a Buy [view article]
Thats why I included link to my previous articles on Pfizer instead of repeating the same thing in this article:www.google.com/cse?cx=... Reply
Pharmaceuticals: Pfizer Is a Buy [view article]
If you had taken the time to explain how they are going to make up for the loss of their income flow from Lipitor your financial analysis might carry some weight. As it is, this smells like an accountants analysis who has no knowledge of the industry. ReplyBiotech Names With Big Potential [view article]
I meant Viropharma, my bad: duh. ReplyBiotech Names With Big Potential [view article]
I've owned this stock in the past. The company seems pretty positive about the prospects for their new drugs and is ramping up overseas operations. I think that tells you something given all the risk regarding "forward looking statements" these days. Reply